Research theme for competitive and other funds (1):
2015 - 2016 Lithium for mild-to-moderate Alzheimer's disease: A randomized double-blind, placebo-controlled study
Papers (38):
Kenji Sakuma, Shinji Matsunaga, Ikuo Nomura, Makoto Okuya, Taro Kishi, Nakao Iwata. Folic acid/methylfolate for the treatment of psychopathology in schizophrenia: a systematic review and meta-analysis. Psychopharmacology. 2018. 1-12
Kishi T, Ikuta T, Oya K, Matsunaga S, Matsuda Y, Iwata N. Anti-dementia Drugs for Psychopathology and Cognitive Impairment in Schizophrenia: A Systematic Review and Meta-analysis. The international journal of neuropsychopharmacology. 2018. 21. 8. 748-757
Taro Kishi, Shinji Matsunaga, Nakao Iwata. The effects of memantine on behavioral disturbances in patients with Alzheimer’s disease: A meta-analysis. Neuropsychiatric Disease and Treatment. 2017. 13. 1909-1928
Taro Kishi, Toshikazu Ikuta, Shinji Matsunaga, Yuki Matsuda, Kazuto Oya, Nakao Iwata. Comparative efficacy and safety of antipsychotics in the treatment of schizophrenia: A network meta-analysis in a Japanese population. Neuropsychiatric Disease and Treatment. 2017. 13. 1281-1302
Taro Kishi, Yuki Matsuda, Shinji Matsunaga, Masatsugu Moriwaki, Yoichiro Otake, Kaku Akamatsu, Tomo Okochi, Shigeki Hirano, Toshihiko Funahashi, Momoko Okuda, et al. Escitalopram versus paroxetine controlled release in major depressive disorder: A randomized trial. Neuropsychiatric Disease and Treatment. 2017. 13. 117-125
THE JAPAN GERIATRICS SOCIETY
, THE JAPANESE SOCIETY OF INTERNAL MEDICINE
, JAPAN SOCIETY FOR DEMENTIA RESEARCH
, JAPANESE PSYCHOGERIATRIC SOCIETY
, The Japanese Society of Psychiatry and Neurology